Mana.bio Presents Broad Improvements to Systemic Lipid Nanoparticle Tolerability by Leveraging a Novel AI-Driven Safety Model

Mana.bio is proud to announce a major leap forward in lipid nanoparticle (LNP) technology, recently presented at the 3rd annual LNP Immunogenicity & Toxicity Summit in Boston. These advancements reflect our commitment to tackling the most pressing challenges in gene therapy, including safety, potency, and tolerability.

By leveraging our AI/ML-enabled platform, Mana.bio has developed new LNP formulations that achieve:

• A 100-fold reduction in cytokine elevation, ensuring better safety profiles.

• Normalized levels of ALT, AST, and platelets, critical biomarkers for systemic safety.

• Over 100% improvement in tolerable doses, allowing safe administration above 2 mg/kg.

  
  

These innovations address industry concerns regarding the safety and re-dosing limitations of LNP-based therapies while enhancing therapeutic efficacy.

Mana.bio remains dedicated to developing groundbreaking solutions that drive the field of gene therapy forward.

Read the full press release here.